This page shows the latest radioligand therapy news and features for those working in and with pharma, biotech and healthcare.
More than 80% of patients highly express a phenotypic biomarker called PSMA, making it a promising diagnostic and therapeutic target for radioligand therapy, Novartis said. ... The trial met its primary endpoint, with Pluvicto demonstrating a
The trial met its primary endpoint, with the PSMA-targeted radioligand therapy demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) after treatment with androgen-receptor
If approved by the European Commission, Pluvicto would be the first and only commercial radioligand therapy for people with advanced prostate cancer in Europe. ... We are committed to exploring the potential of radioligand therapy to address unmet needs
The treatment is the first FDA approved targeted radioligand therapy for mCRPC patients.
Novartis has revealed new data from a phase 3 trial evaluating its targeted radioligand therapy (RLT) in late stage advanced prostate cancer at the 2021 American Society of Clinical Oncology (ASCO) ... This] data from the first phase 3 study of a
We continue to invest in radioligand therapy as one of the four unique platforms of Novartis Oncology. ... compared the radioligand therapy plus best standard of care (SoC) to SoC alone.
More from news
Approximately 4 fully matching, plus 5 partially matching documents found.
No results were found
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....